Anti-cardiolipin and anti-beta 2 glycoprotein I antibodies in patients with type 1 diabetes.

Abstract

To determine the frequency of anti-phospholipid antibodies (aPL) in particular anti-cardiolipin antibodies (aCL) and anti-beta 2 glycoprotein I antibodies (aβ2GPI) in Tunisian patients with type 1 diabetes. One hundred and two patients with type 1 diabetes (34 children, 68 adults) were studied. As control groups, we used sera of 156 adults and 65 children without type 1 diabetes. aCL and aβ2GPI were detected by ELISA. The frequency of aPL was significantly higher in type 1 diabetes patients than in control group (18.6% vs. 5.9%, p <0.001). In patients, aPL were significantly more frequent in adults than in children (25% vs. 5.9%, p =0.04). In the whole group of type 1 diabetes, aCL were significantly more frequent in long-term type 1 diabetes than in inaugural type 1 diabetes (21.2% vs. 7.2%, p =0.04). In adults, aβ2GPI were significantly more frequent in inaugural type 1 diabetes than in controls (20% vs. 1.9%, p <0.001), and the frequency of aCL was significantly higher in long-term type 1 diabetes than in controls (21.9% vs. 1.9%, p <0.001). Female adults with type 1 diabetes had high frequency of aCL and aβ2GPI.